HC Wainwright Issues Positive Estimate for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, up from their previous estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.52) EPS.

Other research analysts have also issued research reports about the stock. B. Riley assumed coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $4.00 price objective for the company. William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research report on Thursday. Finally, Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Friday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $4.92.

Nektar Therapeutics Stock Up 10.0 %

NASDAQ NKTR opened at $0.90 on Monday. The firm has a market cap of $165.42 million, a PE ratio of -1.07 and a beta of 0.65. The company has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.08. Nektar Therapeutics has a 52 week low of $0.65 and a 52 week high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.33. The firm had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.

Hedge Funds Weigh In On Nektar Therapeutics

Several large investors have recently made changes to their positions in NKTR. Two Sigma Securities LLC lifted its stake in shares of Nektar Therapeutics by 56.3% in the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 9,958 shares during the period. Harvest Investment Services LLC acquired a new position in Nektar Therapeutics during the fourth quarter worth $27,000. US Asset Management LLC acquired a new position in Nektar Therapeutics during the fourth quarter worth $31,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the third quarter worth $34,000. Finally, Intech Investment Management LLC acquired a new position in Nektar Therapeutics during the third quarter worth $41,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the completion of the transaction, the insider now directly owns 326,904 shares in the company, valued at $307,289.76. The trade was a 13.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Howard W. Robin sold 46,995 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the completion of the transaction, the chief executive officer now owns 1,195,710 shares of the company’s stock, valued at approximately $1,207,667.10. This represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 165,586 shares of company stock valued at $159,990 in the last ninety days. Insiders own 3.71% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.